Zobrazeno 1 - 7
of 7
pro vyhledávání: '"R. H. Rousell"'
Autor:
S. C. Chu, N. T. Soskel, A. B. Cohen, T. L. Petty, A. S. Buist, D. Holden, M. Wu, R. W. Ashburn, M. Baumann, T. Clark, Ronald G. Crystal, P. E. Epstein, D. P. Meeker, L. Colar, V. Smith, James K. Stoller, B. Burrows, B. Rundquist, Atul C. Mehta, K. O'Neil, D. N. Killian, J. Seidman, R. E. Sandblom, J. Hildesheim, P. Del Buono, B. Begle, Herbert P. Wiedemann, J. Forrester, L. Golden, R. Hitchcock, R. S. Sen, J. Corbett, C. Strange, S. Sherman, J. Drake, J F Jr Tomashefski, Mark D. Schluchter, T. Staats, B. Moore, J. P. McMahan, P. Sartori, M. Judson, R. A. Sandhaus, D. M. Barrett, R. J. Fallat, S. G. Sherer, Gerald J. Beck, C. W. Bell, R. Oser, M. S. Eichenhorn, N. G. McElvaney, Alejandro C. Arroliga, M. J. Krowka, R. F. Sarlin, M. L. Brantly, W. M. Breite, M. Rosenberg, J. Berend, S. Weinberger, S. Jones, D. McManus, C. E. Vreim, K. Johnson, George W. Williams, T. Zeiger, V. Midcalf, J. B. DeMaine, D. Erb, R. Johnston, W. Demicco, P. Barnes, R. H. Rousell, R. C. Hert, A. Kotch, Renliang Zhang, R. S. Schwartz, B. Cameron, J. E. Gadek, G. M. Turino, U. B. Prakash, J. Ryan, D. Webb-Johnson, B. M. Meth, T. E. Walsh, Daniel Laskowski, J. Moss, J. P. Loftin
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 158:49-59
Publikováno v:
Transfusion. 29(3)
The pharmacology of a new pasteurized factor VIII (FVIII) concentrate derived from human blood plasma was studied in 23 adults with hemophilia A. In Part 1 of the study involving six nonbleeding subjects, the mean increase in FVIII activity was 1.43
Autor:
R H Rousell, K M Fox, R J Dobbs, J J Hamblin, E B Raftery, R. W. Portal, N. M. Bass, J. P. P. Stock, C P Aber, C L Berry, G Howitt, J E MacIver, Peter Carson, S P Haydu
Publikováno v:
British medical journal. 2(6044)
In a multicentre trial of streptokinase in acute myocardial infarction 302 patients received an intravenous infusion of 2 500 000 IU of streptokinase over 24 hours, while 293 patients served as controls. Neither group received anticoagulants unless i
Publikováno v:
Vox sanguinis. 54(1)
Evidence for transmission of non-A non-B hepatitis (NANB) was sought in 41 patients with primary immune deficiency who were receiving human intravenous immune globulin (IGIV) over periods ranging from 6 to 15 months at a monthly dosage of 400 mg/kg b
Publikováno v:
Clinical therapeutics. 11(1)
Quality assurance release levels for anti-complementary (AC) activity of a non-modified intravenous immunoglobulin (IGIV, pH 4.25) were reviewed over a period of one year and nine months in an attempt to correlate the incidence of complement-mediated